PhD student Melanoma Genetics: understanding and biomarking the genetic and immunological determinants of melanoma development and patient survival.
A Marie Skłodowska-Curie Early Training Network
This network, bringing together 7 European Universities and 5 collaborating academic and commercial partners, offers 17 Early Stage Research (ESR) PhD training positions for 36 months. The PhD projects will be based around genomics/transcriptomics but with strong immunology, statistics and bioinformatics.
The MELGEN European Training Network (ETN) will create a co-operative environment for research and training in melanoma research, with the ultimate aim of improving precision medicine for patients with this disease. In recent years remarkable progress has been made in melanoma research, which has led to the introduction of the first treatments to prolong life in patients with advanced disease: both targeted treatments and immune therapies. Although genomics has yielded a wealth of information on the genomic alterations in melanoma, further characterisation is urgently needed in order to predict responses to combinations of targeted therapies and MELGEN will address this need. The dramatic responses seen in melanoma patients to immunotherapies indicate that immune responses to melanoma are crucial, and we need to better understand what predicts response in order to improve treatment strategies, particularly in the adjuvant setting. MELGEN will explore host/tumour interactions and detect biomarkers of response to treatment. The academic centres and several commercial partners of this network will address these research questions using unique samples and data sets and the most sophisticated technologies, including genomic and transcriptomic analyses, functional genetic screens, CRISPR genome editing, iPS cell-based disease models, liquid biopsy technology, developmental statistics and bioinformatics.
Further details:
http://www.academictransfer.com